Exploration of treatment options for the management of stage I testicular seminoma

Expert Review of Anticancer Therapy

Volumn 8, Issue 7, 2008, Pages 1081-1090

  Bernal, Federico ^a   Raman, Jay D ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adjuvant radiation; Radiologic imaging; Seminoma; Single agent carboplatin; Surveillance

Indexed keywords

ALPHA FETOPROTEIN; CARBOPLATIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; ETOPOSIDE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ADJUVANT THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; ECHOGRAPHY; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MALE; MALE INFERTILITY; MEDICAL DECISION MAKING; MENTAL STRESS; MORBIDITY; MOTIVATION; MULTIPLE CYCLE TREATMENT; ORCHIECTOMY; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PROGNOSIS; RADIATION DOSE FRACTIONATION; SEMINOMA; THORAX RADIOGRAPHY; ADJUVANT CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; REVIEW; TESTIS TUMOR;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; MALE; NEOPLASM STAGING; ORCHIECTOMY; RADIOTHERAPY, ADJUVANT; SEMINOMA; TESTICULAR NEOPLASMS;

EID: 48849103259     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.7.1081     Document Type: Article

References (59)

1. Jemal A, Siegel R, Ward E et al. Cancer Statistics, 2007. CA Cancer J. Clin. 57(1), 43-66 (2007).
2. Wein AJ, Kavoussi LR, Novick AC, Partin AW, Peters CA (eds.) Campbell-Walsh Urology. Saunders-Elsevier, PA, USA (2007).
3. Huyghe E, Matsuda T, Thonneau P. Increasing incidence of testicular cancer worldwide: a review. J. Urol. 170(1), 5-11 (2003).
4. Carver BS, Sheinfeld J. Germ cell tumors of the testis. Ann. Surg. Oncol. 12(11), 871-880 (2005).
5. Horwich A, Shipley J, Huddart R. Testicular germ-cell cancer. Lancet 367(9512), 754-765 (2006).
6. Mostofi FK. Testicular tumors. Epidemiologic, etiologic, and pathologic features. Cancer 32(5), 1186-1201 (1973).
7. Chung P, Warde P. Surveillance in stage I testicular seminoma. Urol. Oncol. 24(1), 75-79 (2006).
8. Fosså SD, Horwich A, Russell JM et al. Optimal planning target volume for stage I testicular seminoma: a medical research council randomized trial. J. Clin. Oncol. 17(4), 1146 (1999).
9. Josefsen D, Fossi S. The management strategies for stage I seminoma. Clin. Oncol. 17(7), 539-542 (2005).
10. Groll RJ, Warde P, Jewett MA. A comprehensive systematic review of testicular germ cell tumor surveillance. Crit. Rev. Oncol. Hematol., 64(3), 182-197 (2007).
11. Horwich A, Alsanjari N, A'Hern R et al. Surveillance following orchidectomy for stage I testicular seminoma. Br. J. Cancer 65(5), 775-778 (1992).
12. von der Maase H, Specht L, Jacobsen GK et al. Surveillance following orchidectomy for stage I seminoma of the testis. Eur. J. Cancer 29(14), 1931-1934 (1993).
13. Warde P, Specht L, Horwich A et al. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J. Clin. Oncol. 20(22), 4448-4452 (2002).
14. Alomary I, Samant R, Gallant V. Treatment of stage I seminoma: a 15-year review. Urol. Oncol. 24(3), 180-183 (2006).
15. Oldenburg J, Martin JM, Fosså SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J. Clin. Oncol. 24(35), 5503-5511 (2006).
16. Sharda NN, Kinsella TJ, Ritter MA. Adjuvant radiation versus observation: a cost analysis of alternate management schemes in early-stage testicular seminoma. J. Clin. Oncol. 14(11), 2933-2939 (1996).
17. Francis R, Bower M, Brunström G et al. Surveillance for stage I testicular germ cell tumours: results and cost benefit analysis of management options. Eur. J. Cancer 36(15), 1925-1932 (2000).
18. Chan JL, Kabeto MU, Oldread AE et al. The use of preferences to measure the benefit of adjuvant radiation therapy for stage I seminoma. Int. J. Radiat. Oncol. Biol. Phys. 53(4), 934-941 (2002).
19. Ord-Lawson S, Fitch M. The relationship between perceived social support and mood of testicular cancer patients. Can. Oncol. Nurs. J. 7(2), 90-95 (1997).
20. Moynihan C. Testicular cancer: the psychosocial problems of patients and their relatives. Cancer Surv. 6(3), 477-510 (1987).
21. Arai Y, Kawakita M, Hida S et al. Psychosocial aspects in long-term survivors of testicular cancer. J. Urol. 155(2), 574-578 (1996).
22. Logue JP, Harris MA, Livsey JR et al. Short course para-aortic radiation for stage I seminoma of the testis. Int. J. Radiat. Oncol. Biol. Phys. 57(5), 1304-1309 (2003).
23. Travis LB, Curtis RE, Storm H et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J. Natl Cancer Inst. 89(19), 1429-1439 (1997).
24. Niazi TM, Souhami L, Sultanem K et al. Long-term results of para-aortic irradiation for patients with Stage I seminoma of the testis. Int. J. Radiat. Oncol. Biol. Phys. 61(3), 741-744 (2005).
25. Boden G, Gibb R. Radiotherapy and testicular neoplasms. Lancet 261 (DEC29), 1195-1197 (1951).
26. Glanzmann C, Kaufmann P, Jenni R, Hess OM, Huguenin P. Cardiac risk after mediastinal irradiation for Hodgkin's disease. Radiother. Oncol. 46(1), 51-62 (1998).
27. Gyenes G, Gagliardi G, Lax I, Fornander T, Rutqvist LE. Evaluation of irradiated heart volumes in stage I breast cancer patients treated with postoperative adjuvant radiotherapy. J. Clin. Oncol. 15(4), 1348-1353 (1997).
28. Travis LB, Andersson M, Gospodarowicz M et al. Treatment- associated leukemia following testicular cancer. J. Natl Cancer Inst. 92(14), 1165-1171 (2000).
29. Travis LB, Fossa SD, Schonfeld SJ et al. Second cancers among 40 576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 97(18), 1354-1365 (2005).
30. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J. Clin. Oncol. 21(8), 1513-1523 (2003).
31. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J. Clin. Oncol. 22(4), 640-647 (2004).
32. de Wit R, Fizazi K. Controversies in the management of clinical stage I testis cancer. J. Clin. Oncol. 24(35), 5482-5492 (2006).
33. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA, 299(6), 672-684 (2008).
34. Jones WG, Fosså SD, Mead GM et al. Randomized trial of 30 versus 20 Gy in the adjuvant treatment ofstage I testicular seminoma: a report on Medical Research Council Trial TE18, European Organisation for the Research and Treatment of Cancer Trial 30942 (ISRCTN18525328). J. Clin. Oncol. 23(6), 1200-1208 (2005).
35. Niewald M, Freyd J, Fleckenstein J, Wullich B, Rübe C. Low-dose radiotherapy for Stage I seminoma - long-term results. Int. J. Radiat. Oncol. Biol. Phys. 66(4), 1112-1119 (2006).
36. Bieri S, Rouzaud M, Miralbell R. Seminoma of the testis: is scrotal shielding necessary when radiotherapy is limited to the para-aortic nodes? Radiother. Oncol. 50(3), 349-353 (1999).
37. Huddart RA, Joffe JK. Preferred treatment for stage I seminoma: a survey of Canadian radiation oncologists. Clin. Oncol. 18(9), 693-695 (2006).
38. Bajorin DF, Sarosdy MF, Pfister DG et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multiinstitutional study. J. Clin. Oncol. 11(4), 598-606 (1993).
39. Aparicio J, Germa JR, Garcia del Muro XG et al. Risk-adapted management for patients with clinical stage I seminoma: The Second Spanish Germ Cell Cancer Cooperative Group Study. J. Clin. Oncol. 23(34), 8717-8723 (2005).
40. Oliver RTD, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 366(9482), 293-300 (2005).
41. Loehrer PJ Sr, Bosl GJ. Carboplatin for stage I seminoma and the Sword of Damocles. J. Clin. Oncol. 23(34), 8566-8569 (2005).
42. Powles T, Robinson D, Shamash J et al. The long-term risks of adjuvant carboplatin treatment for stage I seminoma of the testis. Ann. Oncol. 19(3), 443-447 (2008).
43. Christoph F, Weikert S, Miller K, Schrader M. New guidelines for clinical stage I testicular seminoma? Oncology 69(6), 455-462 (2005).
44. Gilligan T, Oh WK, Kantoff PW. Carboplatin for stage I seminoma. J. Clin. Oncol. 24(18), 2971-2972 (2006).
45. Martin JM, Panzarella T, Zwahlen DR, Chung P, Warde P. Evidence-based guidelines for following stage 1 seminoma. Cancer 109(11), 2248-2256 (2007).
46. Karakiewicz PI, Hutterer GC. Predictive models and prostate cancer. Nat. Clin. Pract. Urol. 5(2), 82-92 (2008).
47. Neill M, Warde P, Fleshner N. Management of low-stage testicular seminoma. Urol. Clin. North Am. 34(2), 127-136 (2007).
48. Carolyn C. Getting to personalized cancer medicine. Cancer 110(8), 1641-1643 (2007).
49. Garman KS, Nevins JR, Potti A. Genomic strategies for personalized cancer therapy. Hum. Mol. Genet. 16(R2), R226-R232 (2007).
50. Martin JM, Joon DL, Ng N et al. Towards individualised radiotherapy for Stage I seminoma. Radiother. Oncol. 76(3), 251-256 (2005).
51. Shariat Sf, Margulis V, Lotan Y, Montorsi F, Karakiewicz PI. Nomograms for bladder cancer. Eur. Urol. (2008) (Epub ahead of print).
52. Duchesne GM, Horwich A, Deamaley DP et al. Orchidectomy alone for stage I seminoma of the testis. Cancer 65(5), 1115-1118 (1990).
53. Horwich A, Alsanjari N, A'Hern R et al. Surveillance following orchidectomy for stage 1 testicular seminoma. Br. J. Cancer 65(5), 775-778 (1992).
54. Ramakrishnan S, Champion AE, Dorreen MS, Fox M. Stage I seminoma of the testis: is post-orchidectomy surveillance a safe alternative to routine postoperative radiotherapy? Clin. Oncol. 4(5), 284 (1992).
55. Chung P, Parker C, Panzarella. T et al. Surveillance in stage 1 testicular seminoma - risk of late relapse. Can. J. Urol. 9(5), 1637-1640 (2002).
56. Parker C, Milosevic M, Panzarella T et al. The prognostic significance of the tumour infiltrating lymphocyte count in stage I testicular seminoma managed by surveillance. Eur. J. Cancer 38(15), 2014 (2002).
57. Daugaard G, Petersen PM, Rorth M. Surveillance in stage I testicular cancer. APMIS 111(1), 76-85 (2003).
58. Aparicio J, Garcia del Muro X, Maroto P et al. Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma. Ann. Oncol. 14(6), 867-872 (2003).
59. Choo R, Thomas G, Woo T et al. Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma. Int. J. Radiat. Oncol. Biol. Phys. 61(3), 736 (2005).